What’s Next? Five Things To Look Out For In April

Japan Prepares Further Round Of Price Revisions; US Combigan Patents To Lapse

In the month ahead, Japanese firms are set to be hit with further price cuts to their generics, while Eagle Pharmaceuticals will throw off the restraints for its Pemfexy (pemetrexed) 505(b)(2) version of Eli Lilly’s Alimta.

What's Next Image

From 1 April, Japan’s Ministry of Health, Labour and Welfare will implement its next wide-ranging revision of drug prices. They are set to bring down the average reimbursement price under the national health insurance system by an average of 6.69%. (Also see "Too Fast, Too Much? Japan Cuts Prices By 6.7% As Annual Revisions Bite" - Pink Sheet, 30 March, 2022.)

Generic drugs for which the market share exceeded 80% for the last two years will receive hefty price cuts

More from Biosimilars

More from Products